Rare Disease Therapies: Health Systems & Industry Partnerships

Okay, here’s a⁢ breakdown of the provided text, focusing on the key points and summarizing the interview excerpt with David Mitchell:

Overall Topic: The evolving relationship between pharmaceutical industry‍ and health systems, specifically focusing on access to innovative therapies, particularly for rare diseases.

Key Points from David Mitchell’s Interview:

* Shift to Strategic partnership: The relationship has moved from a simple “transactional” one to a genuine “strategic partnership” focused on⁤ the patient. Both industry and health systems are working together to get therapies to the right patients and ensure optimal outcomes.
* Proactive Approach: The health system is⁤ now proactively engaging with manufacturers early in the drug development ⁣process. This allows them to anticipate access barriers and plan solutions before a drug is launched.
* From Reactive to ⁤Proactive: Previously, the system was reactive, dealing with access issues after ‍ a drug was available. The new collaborative approach allows for ‍pre-emptive problem-solving.
* Patient-Centric‍ Focus: The‍ core of the evolving relationship is a shared commitment to putting the patient at the center⁣ of care.

In essence,Mitchell is describing a move towards a more collaborative,forward-thinking approach to bringing new medications to patients,with a ‍focus⁤ on anticipating and resolving access challenges before they arise.

Additional Notes from the Text:

* The interview is with The American Journal of Managed Care (AJMC).
* The interview is about trade relationship strategy in a health system.
* There is ⁤a link to a resource‍ on rare diseases: https://www.ajmc.com/compendium/raredisease

* There is an⁣ image⁣ of‍ David Mitchell, PharmD, MBA, from UC Davis Health.
* The transcript has been lightly edited ⁤for clarity.

Let me know if you’d like me to elaborate on⁤ any specific aspect of this text or if ⁣you have further questions!